fbpx Skip to main content
 

Search

When the COVID-19 pandemic began, Johnson & Johnson mobilized to develop a COVID-19 vaccine,
pursuing a commitment to global equity.
When the COVID-19 pandemic began, Johnson & Johnson mobilized to develop a COVID-19 vaccine,
pursuing a commitment to global equity.
When the COVID-19 pandemic began,
Johnson & Johnson
mobilized to develop
a COVID-19 vaccine,
pursuing a commitment
to global equity.

Title

COVID19 Response

 

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we have worked to protect people, especially the most vulnerable, from the world’s most challenging and wide-reaching infectious diseases like COVID-19. That’s why from the very beginning, we took a stand against COVID-19 on a global scale.
 

We are proud of our efforts to develop, scale-up, manufacture and make available our COVID-19 vaccine globally, which involved an unprecedented mobilization within our company and with our partners. Our COVID-19 vaccine has helped protect millions of people around the world, and we continue to focus our efforts on ensuring our vaccine is available for people most in need.



 

For the status of Janssen's COVID-19 Vaccine in your country, click here.

 

 

For COVID-19-related media inquiries, click here.

 

Resources on COVID-19 and Vaccines

 

Our Commitment to Safety & Transparency

 

The safety and well-being of the people who use our products is our first priority. We actively monitor safety reports as part of our routine pharmacovigilance activities and work closely with healthcare authorities and regulators to ensure we provide transparent and accurate information to healthcare providers and the public.

Our Commitment to the Communities Most Impacted by COVID-19

 

Our COVID-19 response has been guided by a commitment to global equity. We are proud of our efforts to develop a vaccine that could be stored and shipped around the world through standard vaccine distribution channels, including in rural and remote areas, and we implemented a global clinical development plan which studied the vaccine in diverse populations in Asia, Africa, Latin America, the U.S. and Europe. We have been committed to helping to ensure vaccines reach people in need and have engaged in several initiatives to help countries and NGOs address the highly complex challenge of vaccine uptake. To date, more than 85 percent of our vaccine doses have been distributed to low- and middle-income countries.